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Abstract New thiopurines with the propargylthio, pyrro-
lidinobutynylthio, sulfenamide, and sulfonamide groups in
the pyrimidine ring were synthesized. The anticancer
activity of these compounds and previously obtained
2- or 6-substituted azathioprine analogs and dialky-
laminoalkylthiopurines were tested in vitro against three cell
lines: glioblastoma SNB-19, melanoma C-32, and human
ductal breast epithelial tumor T47D. 2-Chloro-7-methyl-6-
pyrrolidinobutynylthiopurine (5b) was the most potent
compound against SBN-19 and C-32 cell lines with the ac-
tivity similar to cisplatin (EC50 = 5.00 and 7.58 lg/ml, re-
spectively). The dialkylaminoalkylthio derivatives (4b, 4c,
4e, and 4f) showed good activity against SBN-19 cell line
(EC50\ 10 lg/ml). The azathioprine analogs (2a, 2b, and
3a) were more active than azathioprine against SBN-19 and
C-32 cell lines. The sulfenamide and sulfonamide deriva-
tives of purine were very weak active against tested cell
lines. All studied thiopurines were less toxic than cisplatin.
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Introduction
The sulfur-containing purines: 6-mercaptopurine, 6-thiogua-
nine, and azathioprine, have been considered as important
and effective drugs used in cancer chemotherapy, for im-
munosuppression in kidney or heart transplantation and au-
toimmune diseases (Steurer et al., 2006; Hawwa et al., 2008;
Relling et al., 2013; Rao et al., 2013). 6-Mercaptopurine is
widely used as an antileukemic agent in the lymphoprolif-
erative disorders, including lymphoma, childhood acute
lymphoblastic leukemia, and other neoplastic conditions
(Hawwa et al., 2008; Prima et al., 2013; Miron et al., 2009).
Azathioprine, but also 6-mercaptopurine exert immunosup-
pressive effects and are the treatments of choice for severe
chronic inflammatory diseases such as rheumatoid arthritis,
ulcerative colitis, Crohn’s disease, inflammatory bowel dis-
eases, systemic lupus erythematosus, and multiple sclerosis
(Aldinucci et al., 2010; Colombel et al., 2010; Daehn and
Karran, 2009). Various pharmacological effects of synthetic
thiopurines including antiviral, antibacterial, antitumor, and
antifungal activity (Lech-Maranda et al., 2006; Rao et al.,
2013) were developed for treatment of patients with infec-
tions of human immunodeficiency virus (HIV) and infections
caused by herpes and hepatitis virus (Rao et al., 2013; Schow
et al., 1997; Chang-Hyun et al., 2001).
However, the use of thiopurines is limited by their
toxicities, which include hepatotoxicity, myelosuppression,
pancreatitis, and allergic reactions (Prima et al., 2013). For
this reason, many thiopurine derivatives and analogs have
been synthesized for evaluation of their biological ac-
tivities and reduced toxicity. Recently, 9-substituted
derivatives of 6-(t-butoxycarbamylaminohexyl)thiopurine
were obtained which showed moderate antibacterial ac-
tivity (Rao et al., 2013); a series of 6-mercaptopurine
analogs with 1,2,3-triazole or steroid rings exhibited
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promising antimalarial and antileishmanial activities
(Corrales et al., 2011); and biologically active 6-al-
lyldithiopurine and its riboside inhibited cell proliferation
and induced apoptosis (Miron et al., 2009).
Heterocyclic sulfonamides are used as carbonic anhydrase
inhibitors, antibacterial, anti-inflammatory, analgesic, hypo-
glycemic, antifungal, and antiviral agent (Joseph et al., 2010;
Guzel et al., 2009; Azab et al., 2013; El-Sayed et al., 2011;
Veisi et al., 2011). It is known that aryl and heteroaryl sul-
fonamides may act as antitumor agents through perturbation
of cell cycle in the G1 phase, distribution of microtubule
assembly, or angiogenesis inhibition. They reverse the effect
of tumor acidification, consequently inhibit the growth of
cancer cell, and suppress tumor invasion mediated by the
carbonic anhydrase active side (Zn2?) and so inhibit the cat-
alytic ability of this enzyme (El-Sayed et al., 2011). Indisulam
(E7070) is a novel sulfonamide anticancer agent currently in
phase II clinical development for the treatment of several
types of cancer. It was shown to act as a nanomolar inhibitor of
carbonic anhydrase isoform IX (Sławin´ski et al., 2013; Mirian
et al., 2011).
The sulfamoyl group has been extensively utilized as an
activity-modifying substituent in many different classes of
drugs. The synthesis of 2-substituted 7- or 9-methylpurines
containing a sulfanilamide group at the positions 2, 6, or 8
of the purine ring with moderate antibacterial activity was
reported by the reaction of chloropurines with sodium
sulfanilamide (Beaman et al., 1966). Structural modifica-
tion of the amino group at C-6 atom of adenosine leads to
selective A1 receptor agonists, while modification at C-2
atom confers high potency and selectivity on A2A recep-
tors. The synthesis of N-9- and 6-amino monosulfony-
ladenine and disulfonyladenine derivatives and its
sulfonylated nucleoside with high potency and selectivity
on A1 and A2A receptor agonists has been described (Zinic
et al., 2001). A number of 6-sulfenamide, sulfinamide, and
sulfonamide derivatives of 6-mercaptopurine, 6-thiogua-
nine, and related ribonucleosides have been synthesized
and evaluated for antileukemic activity in mice (Revankar
et al., 1990). It is quite interesting that a subtle change to an
oxidized sulfur atom in the form of sulfonamide resulted in
a new group of purine derivatives possessing significant
antitumor properties. Majority of the tested compounds
exhibited very significant anti-L1210 cell activity (Re-
vankar et al., 1990; Robins et al., 1991).
Oligonucleotides containing 1-alkynyl-6-thiopurine or
6-thioguanine bases demonstrate potent antiviral activity in
several assays, including the human immunodeficiency virus
reverse transcriptase enzyme assay (Broom et al., 1997). The
purine derivatives possessing the alkynyl groups at position 6
are cytokinin analogs with profound plant growth-stimulating
effect and have attracted considerable interest as potential
anticancer compounds. All 6-phenylacetylenes and certain
enyne of the purine are highly toxic against K-562 cells and
exhibit cytotoxic activity against a human chronic myeloge-
nous leukemia cell line comparable to well-known anticancer
drugs (6-mercaptopurine and fludarabine) (Brathe et al.,
2003). Many adenine and adenosine derivatives with 2-, 6-, or
8-alkynyl substituents are selective adenosine subtypes A1,
A2A, A2B, and A3 receptor antagonists. 2-Alkynyl-8-aryl
adenine derivatives bear methyl or an amide moiety at the
position 9, as A2B receptor antagonists have hypoglycemic
activity and may be used as antidiabetic agents (Harada et al.,
2001). Stimulating A2A receptor by 2-adenosine propargyl
phenyl ether composition resulted in vasodilating activity and
potential of using in coronary artery disease (Zablocki et al.,
2001). Introduction of alkynyl chains on C-8 atom of adeno-
sine led to very selective antagonists of the A3 receptor
(Volpini et al., 2001). Some 2-alkynyl and 2,(6-amino)di-
alkynyl adenosine derivatives show high affinity and different
degrees of selectivity for A1, A2A, and A3 receptor (Volpini
et al., 2001).
Our previous research demonstrated the effective synthesis
of thiosubstituted purines such as 2- or 6-substituted aza-
thioprine analogs (Kowalska and Pluta, 2008; Kowalska et al.,
2009) and dialkylaminoalkylthiopurines (Kowalska and Plu-
ta, 2012). The aim of this study was to elaborate synthesis of
new thiopurines with the propargylthio, pyrrolidinobu-
tynylthio, sulfenamide, and sulfonamide groups in the
pyrimidine ring, to examine anticancer activity of not only
those compounds but also previously synthesized thiopurines
and to discuss the structure–activity relationship.
Result and discussion
Chemistry
All thiosubstituted 7-methylpurines were obtained from
2-substituted 7-methylpurine-6-thiones 1a–c and 7-methyl-
purine-2,6-dithiones 1d. Purinyl sulfides 2–4 with the
pharmacophoric 1-methyl-4-nitroimidazol-5-yl and dialky-
laminoalkyl groups in positions 2 and 6 were obtained ac-
cording to the procedures published previously (Kowalska
and Pluta, 2008; Kowalska et al., 2009; Kowalska and Pluta,
2012). The alkynylthio derivatives 5 were obtained from
2-chloro derivative 1a and propargyl bromide and further via
Mannich reaction with pyrrolidine (Scheme 1).
The traditional and general method for preparing sul-
fonamides is based on reaction of sulfonyl chloride with
ammonia or amines. The aryl sulfonyl chlorides may be
obtained from thiols, sulfides, thioacetals, or thiocarbami-
nes by oxidative chlorination with chlorine gas in aqueous
acid (Veisi et al., 2011; Mirian et al., 2011; Ashfaq et al.,
2013; Narasaiah et al., 2012; Rehman et al., 2012).
2-Chloro-7-methyl-6-purinethione 1a was chosen as a
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model compound to prepare S-benzylthiopurine 6. It is
known that azinesulfonyl chlorides with the chlorosulfonyl
group in aza-activated positions readily lose sulfur dioxide
to form chloroazines (Beaman and Robins, 1961; Beaman,
1963; Revankar et al., 1990).
Two-step synthesis of purinesulfonamide 8 via oxida-
tion and chlorination of sulfide 6 with chlorine in acetic
acid and subsequent transformation of sulfonyl chloride 7
with ammonia, diethylamine, or aniline failed. In this case,
the highly instable chlorosulfonyl group lost sulfur dioxide,
and resulted chloropurine reacted with ammonia and ami-
nes to give 2-chloro-6-amine derivatives 9a–c with
71–86 % yield (Scheme 2).
Therefore, the sulfonamide compounds were obtained
from purinethione via amination and oxidation. The pro-
cedure of S-amination of azinethiones with chloramine
solution has been widely used in the preparation of purine-,
pyridine-, pyrimidine-, and benzothiazolesulfenamides
(Revankar et al., 1990; Robins et al., 1991; Hurley and
Robinson, 1965; Schoenwald et al., 1984). For 2-Substi-
tuted 7-methyl-6-purinethiones 1a–c, S-amination with a
chloramine solution at 0 C to sulfenamide 10a–c in
85–92.5 % yield was carried out. In the case of pur-
inedithione 1d, two products were obtained: disubstituted
compound as the main product, purine-2,6-disulfenamide
10e (66 % yield) and purine-6-sulfenamide 10d (17.5 %
yield). Treatment of sulfenamides 10 with 4 molar
equivalent of 3-chloroperoxybenzoic acid (MCPBA) at
room temperature in ethanol gave purinesulfonamides 8a–
d in 66–79 % yield. Lesser equivalents of MCPBA led to
sulfenamides (Revankar et al., 1990).
The structure of all new compounds was determined by
the spectral data analysis: 1H and 13C NMR, EI, CI or FAB
MS, and HR MS. 1H NMR spectra of new compounds
revealed H-8, NCH3 proton signals, and protons from C-2
(OCH3, SCH3) and C-6 (CH2C6H5, NH2, N(C2H5)2,
NHC6H5, SCH2CCH, SCH2CCCH2NC4H8, SNH2, SO2-
NH2) substituents.
13C NMR spectra showed primary,
secondary, tertiary, and quaternary carbon signals. In order
to assign all of these signals, 2D NMR techniques
(HSQC—the primary, secondary, and tertiary carbon atoms
connected with the hydrogen atoms and HMBC—the pri-
mary, tertiary, and quaternary carbon atoms connected with
the hydrogen atoms via two and mainly three bonds) for
selected compounds (5a, 10e) were used. For compounds
5a, in the HSQC spectrum the H-8 proton at 8.59 ppm
correlated with the signal at 151.09 ppm (C-8), the SCH2
proton at 4.22 ppm correlated with the signal at 18.09 ppm
(C, SCH2), and the proton at 4.04 ppm (NCH3) correlated
with the signal at 34.84 ppm (C, NCH3). The HMBC
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Scheme 2 Synthesis of amine 9, sulfenamide 10, and sulfonamide 8 derivatives of purines
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spectrum revealed correlation via three bonds between the
H-8 proton at 8.59 ppm and the carbon signals at
34.84 ppm (C, NCH3), at 123.16 ppm (C-5), and at
160.52 ppm (C-4). The proton signal at 4.22 ppm (H,
SCH2) correlated with the signals of carbon atoms via two
bonds at 79.55 ppm (C, CCH) and via three bonds at
74.67 ppm (C, CH) and at 153.99 ppm (C-6). The proton
signal at 4.04 ppm (H, NCH3) correlated via three bonds
with the signals at 123.16 ppm (C-5) and at 151.09 ppm
(C-8). The proton–carbon correlation was presented in
Scheme 3.
Anticancer activity
For the biological tests, 20 thiopurines of five types were
selected:
(a) the azathioprine analogs containing the methylni-
troimidazolylthio group in position 2 (compounds 2a,
2b), in position 6 (3a–c), and in both positions (3d),
(b) the dialkylaminoalkylthio derivatives containing that
substituent with an open-chain amine group in
positions 6 (4a, 4b), 2 and 6 (4c, 4d) and with a
cyclic amine group (pyrrolidine, piperidine, and
morpholine) in positions 2 and 6 (4e–g),
(c) the alkynylthio derivatives containing the propynylth-
io (5a) and pyrrolidinobutynylthio (5b) groups,
(d) the sulfenamide derivative (10a),
(e) the sulfonamide derivatives with that group in posi-
tions 6 (8a–c), and 2 and 6 (8d).
The anticancer activity of the obtained compounds was
investigated in vitro using cultured glioblastoma SNB-19,
melanoma C-32, and human ductal breast epithelial tumor
T47D cell lines. Normal human fibroblasts (HFF-1) were
used as a control, and azathioprine and cisplatin as refer-
ence drugs. Table 1 contains the activity of thiopurines as
the EC50 values.
The most active was 2-chloro-7-methyl-6-pyrrolidi-
nobutynylthiopurine (5b) with the EC50 values of 5.00
and 7.58 lg/ml against SNB-19 and C-32 cell lines,
comparable to the cisplatin effect. This compound ex-
hibited good selectivity and low toxicity, being weak
active against T47D cell line and normal fibroblasts
HFF-1. The introduction of the pyrrolidine ring to the
alkynyl chain enhanced the activity (compound 5b vs.
5a).
Good activity against SNB-19 cell line was observed for
the dialkylaminoalkylthio derivatives (4b, 4c, 4e, and 4f)
with the EC50 values below 10 lg/ml. The compounds with
the ethyl chain were more active than those with the propyl
chain. The most active was compound 4e with the two
pyrrolidinoethylthio groups. The activity against other cell
lines was lesser as well as their toxicity.
The azathioprine analogs with the imidazolylthio group
in position 2 were more active than those with that group in
position 6 with an exception of compound (3a) which ex-
hibited good activity against C-32 cell line. The most ac-
tive azathioprine analogs (2a, 3a) possessed the chlorine
atom in position 2 or 6. Both compounds were more active
than azathioprine (against first two cell lines) and com-
pounds containing the methoxyl and thioalkyl groups (2b,
3b, 3c). Compound 3d with two imidazolylthio groups
turned out to be unexpectedly inactive. In our opinion, such
an effect was the result of the unusual spatial arrangement
of those groups directed to N-1 atom with the donor–ac-
ceptor interaction between the imidazole rings, as it was
observed in X-ray analysis of the monocrystal 3d
(Kowalska et al., 2009).
The sulfenamide and sulfonamide derivatives are very
weak active or inactive. The glioblastoma SNB-19 was
most sensitive and breast tumor T47D least sensitive cell
line for thiopurines. All studied compounds were less toxic
than cisplatin.
Conclusion
In search for novel thiopurine derivatives, we described
synthesis of 2-chloro-6-alkynylthio-7-methylpurines 5a, 5b
from 2-chloro derivative and propargyl bromide and fur-
ther via Mannich reaction with pyrrolidine. Other types of
thiopurines bearing the sulfenamide 10a–e and sulfon-
amide 8a–d groups were obtained through S-amination of
purinethiones 1a–d and oxidation with 3-chloroper-
oxybenzoic acid.
New thiopurines 5, 8, and 10, previously synthesized
azathioprine analogs 2 and 3, and dialkylaminoalkylth-
iopurines 4 were investigated as antitumor agents. The
most potent compound against SBN-19 and C-32 cell lines
was 2-chloro-7-methyl-6-pyrrolidinobutynylthiopurine 5bScheme 3 2D NMR experiments for compound 5a
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with the activity similar to cisplatin. The dialky-
laminoalkylthio derivatives 4b, 4c, 4e, and 4f showed good
activity against SBN-19 cell line. The azathioprine analogs
2a, 2b, and 3a were more active than azathioprine against
SBN-19 and C-32 cell lines. The sulfenamide and sulfon-
amide derivatives of thiopurine were very weak active
against tested cell lines. All studied thiopurines were less
toxic than cisplatin.
Experimental
6-Substituted derivatives of 7-methyl-2-(1-methyl-4-ni-
troimidazol-5-ylthio)purines 2a–b were prepared from
7-methyl-2,6-di(1-methyl-4-nitroimidazol-5-ylthio)purine
3d exploiting different reactivity of the imidazolylthio
groups toward nucleophilic reagents (Kowalska et al.,
2009). 2-Substituted derivatives of 7-methyl-6-(1-methyl-4-
nitroimidazol-5-ylthio)purines 3a–d were obtained in the
reaction of 6-purinethiones with 5-chloro-1-methyl-4-ni-
troimidazole in 70 % ethanol (Kowalska and Pluta, 2008).
2-Substituted 6-(dialkylaminoalkylthio) 4a–b and 2,6-bis
(dialkylaminoalkylthio) derivatives 4c–g were obtained
via the direct S-dialkylamination of the appropriate
purinethiones (Kowalska and Pluta, 2012). All commer-
cially available organic solvents and reagents were from
Sigma-Aldrich and Chempur and were used without further
purification.
The melting points were determined in open capillary
tubes on a Boetius melting point apparatus and were un-
corrected. 1H NMR spectra were recorded on a Bruker
AVANS 300 spectrometer operating at 300 MHz and
75 MHz for 1H and 13C nuclei, respectively, in deute-
rochloroform and dimethyl sulphoxide-d6 with tetram-
ethylsilane as internal standard. Shifts were given in ppm,
coupling constant (J) values were presented in hertz (Hz),
and the abbreviations were as follows: s (singlet), d (dou-
blet), t (triplet), and m (multiplet). Electron impact (EI
MS), chemical ionization (CI MS), fast atom bombardment
(FAB MS), and high-resolution (HR MS) (in the m-ni-
trobenzyl alcohol and glycerol matrix) mass spectra were
run on a Finnigan MAT 95 spectrometer at 70 eV. The
reactions were monitored by thin-layer chromatography
(TLC) using aluminum sheets coated with silica gel 60F254
(Merck) and chloroform–ethanol (9:1) as the solvents.
Purity of the synthesized compounds was confirmed by
TLC in the same way. Spots were detected by their ab-
sorption under UV light (k = 254 nm), and the chro-
matograms were further visualized by iodine vapor.
Column chromatography separations were carried out with
Merck Kieselgel 60 or aluminum oxide 90 (Merck) using a
mixture of chloroform–ethanol (99:1, v/v) as an eluent.
Synthesis of 2-chloro-6-(prop-2-ynylthio)-7-methylpurine
5a Propargyl bromide (0.17 g, 1.44 mmol) was added to
a solution generated from the reaction of 2-chloro-7-
methyl-6-thiopurine (0.2 g, 1 mmol) with t-BuOK (0.16 g,
1.44 mmol) in 10 ml of DMF at room temperature for
0.5 h. The reaction mixture was stirred for an additional
24 h at room temperature and then added to 25 ml of
water. The resulted solid was filtered off and washed with
water to give compound 5a. It was obtained as a pale
yellow solid (0.22 g, 92 %); mp 183–184 C (EtOH); 1H
NMR (DMSO-d6), d: 3.26 (t, J = 2.2 Hz, 1H, CH), 4.04 (s,
3H, NCH3), 4.22 (d, J = 2.2 Hz, 2H, SCH2), 8.59 (s, 1H,
H-8); 13C NMR (DMSO-d6), d: 18.09 (CH2, SCH2CCH),
34.84 (CH3, NCH3), 74.67 (CH, SCH2CCH), 79.55 (C,
SCH2CCH), 123.00 (C, C-5), 151.09 (CH, C-8), 152.28 (C,
C-2), 153.99 (C, C-6), 160.52 (C, C-4); HSQC NMR, d:
8.59 (H-8) correlated with 151.09 (C-8), 4.22 (H, SCH2)
correlated with 18.09 (C, SCH2), 4.04 (H, NCH3) corre-
lated with 34.84 (C, NCH3); HMBC NMR, d: 8.59 (H-8)
correlated with 34.84 (C, NCH3), 123.00 (C-5), and 160.52
(C-4), 4.22 (H, SCH2) correlated with 79.55 (C, CCH),
74.67 (C, CH), and 153.99 (C-6), 4.04 (H, NCH3) corre-
lated with 123.00 (C-5) and 151.09 (C-8); EIMS m/z 238
[M]? (34.5), 240 [M?2] (12), 203 [M-Cl] (39), 133 [M-Cl,
Table 1 Antiproliferative activity of thiopurines
Compound Antiproliferative activity EC50 (lg/ml)
SBN-19 C-32 T47-D HFF-1
2a 17.92 21.77 41.11 [50
2b 33.26 35.33 49.60 [50
3a 30.38 12.79 [50 34.93
3b [50 [50 [50 [50
3c [50 [50 48.63 [50
3d [50 [50 [50 [50
4a 28.77 22.47 41.27 [50
4b 8.45 [50 [50 [50
4c 9.82 33.55 24.00 40.00
4d 36.28 [50 [50 [50
4e 7.95 27.05 38.40 35.41
4f 9.18 21.80 32.25 45.50
4g [50 [50 [50 [50
5a 30.95 35.35 44.30 48.95
5b 5.00 7.58 46.00 43.12
8a [50 [50 [50 [50
8b 35.02 [50 [50 [50
8c [50 [50 [50 [50
8d [50 [50 [50 [50
10a [50 [50 [50 [50
Azathioprine 37.20 35.62 39.00 55.88
Cisplatin 4.45 6.28 8.79 30.00
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-SCH2CCH] (55), 39 [CH2CCH] (100); HREIMS m/z
[M]? calcd. for C9H7ClN4S 238.0079, found 238.0076.
Synthesis of 2-chloro-6-(4-N-pyrrolidinylbut-2-ynylthio)-7-
methylpurine 5b To a mixture of propargyl derivative 5a
(0.24 g, 1 mmol) and paraformaldehyde (0.06 g, 2 mmol) in
5 ml of dry dioxane, pyrrolidine (0.14 g, 2 mmol) and CuCl
(0.01 g) were added. The reaction mixture was stirred at
temperature 70 C for 2 h. After cooling, the resulting solid
was filtered off and purified by column chromatography
(silica gel, CHCl3, CHCl3–EtOH, 99:1 v/v) to give compound
5b. It was obtained as a pale yellow solid (0.31 g, 96 %); mp
129–130 C (EtOH); 1H NMR (CDCl3), d: 2.13 (m, 8H,
4CH2), 3.12 (t, J = 2.2 Hz, 2H, SCH2), 3.62 (t, J = 2.2 Hz,
2H, CCH2), 4.19 (s, 3H, NCH3), 8.25 (s, 1H, H-8);
13C NMR
(DMSO-d6), d: 18.77 (CH2, SCH2CC), 23.68 (2CH2), 34.86
(CH3, NCH3), 42.58 (CH2, CCH2), 51.86 (2CH2, NCH2),
79.15 (C, SCH2CC), 80.01 (C, SCH2CC), 123.16 (C, C-5),
151.08 (CH, C-8), 152.35 (C, C-2), 154.24 (C, C-6), 160.50
(C, C-4); CIMS m/z 322 [M?1]? (6.5), 324 [M?1?2] (2.5),
167 [M?1-SCH2CCCH2NC4H8] (9.5), 72 [C4H8NH2]
?
(100); HRFABMS m/z [M?H]? calcd. for C14H17ClN5S
322.0893 found 322.0893.
Synthesis of 2-chloro-6-benzylthio-7-methylpurine 6 2-
Chloro-6-benzylthio-7-methylpurine 6 was prepared from
2-chloro-7-methyl-6-purinethione 1a (0.2 g, 1 mmol) by
alkylation with benzyl chloride (0.25 g, 2 mmol) at room
temperature in 4 % aqueous KOH solution (5 ml). After
30 min, the crude product was precipitated, filtered off,
washed with water, and crystallized from benzene. It was
obtained as a pale yellow solid (0.265 g, 91.5 %); mp
131–132 C (benzene); 1H NMR (CDCl3), d: 4.07, (s, 3H,
NCH3), 4.64 (s, 2H, CH2), 7.38 (m, 5Harom), 7.98 (s, 1H,
H-8); 13C NMR (DMSO-d6), d: 33.39 (CH2, SCH2), 34.84
(CH3, NCH3), 122.72 (C, C-5), 127.98 (CH, p-CH), 128.99
(2CH, m-CH), 129.84 (2CH, o-CH), 137.12 (C, CCH2),
150.79 (CH, C-8), 152.26 (C, C-2), 155.46 (C, C-6), 160.33
(C, C-4); EIMS m/z 290 [M]? (100), 292 [M?2] (28.5),
199 [M-C6H5CH2]
? (87); HREIMS m/z [M?] calcd. for
C13H11ClN4S 290.0392 found 290.0385.
Chlorination and amination of 2-chloro-6-
benzylthio-7-methylpurine 6
The chlorinolysis was carried out by passing chlorine gas
into a stirred mixture composed of 2-chloro-6-benzylthio-
7-methylpurine 6 (0.29 g, 1 mmol), 3 ml of chloroform,
and 3 ml of 80 % acetic acid cooled at 5 C. The passage
of chlorine gas was continued for 30 min, and then the
mixture was poured into 10 ml of ice water. The chloro-
form layer was separated, and aqueous layer was extracted
with chloroform (2 9 5 ml). The chloroform extracts were
combined, washed with water, dried over anhydrous sodi-
um sulfate, and evaporated in vacuo to give an oil residue.
In order to remove benzyl acetate and benzyl chloride, the
residue was triturated with ice-cold dry ether and the ether
layer was separated. The mixture of obtained oil (0.26 g,
1 mmol), and 25 % aqueous ammonia (2.5 ml) or diethy-
lamine (0.22 g, 3 mmol) in 10 % NaOH solution or aniline
(0.19 g, 2 mmol) in 2.5 ml of benzene was stirred at
40–45 C for 2–6 h. The resulted solid was filtered off (in
the case of the reaction with ammonia, the excess of am-
monia was removed in vacuo and the residue was diluted
with water up to volume 2.5 ml) to give compounds 9a–c.
Products were purified by a column chromatography (alu-
minum oxide, CHCl3–EtOH, 99:1 v/v) to give:
2-Chloro-6-amine-7-methylpurine 9a was obtained as a
white solid (0.15 g, 82 %); mp 248–249 C (EtOH), lit. mp
250 C (Adams and Whitmore, 1945); 1H NMR (DMSO-
d6), d: 3.97 (s, 3H, NCH3), 7.46 (s, 2H, NH2), 8.20 (s, 1H,
H-8); 13C NMR (DMSO-d6), d: 34.29 (CH3, NCH3),
111.12 (C, C-5), 147.27 (CH, C-8), 153.03 (C, C-2), 153.17
(C, C-6), 161.50 (C, C-4); EIMS m/z 183 [M]? (100), 185
[M?2] (29); HREIMS m/z [M]? calcd. for C6H6ClN5
183.0311 found 183.0307.
2-Chloro-6-diethylamine-7-methylpurine 9b was ob-
tained as a white solid (0.20 g, 84 %); mp 106–107 C
(EtOH), lit. mp 107 C (Adams and Whitmore, 1945); 1H
NMR (DMSO-d6), d: 1.17 (t, J = 7.7 Hz, 6H, 2 9 CH3
CH2N), 3.52 (q, J = 7.7 Hz, 4H, 2 9 CH3CH2N), 3 0.94 (s,
3H, NCH3), 8.37 (s, 1H, H-8);
13C NMR (DMSO-d6), d:
12.93 (2CH3, NCH2CH3), 35.63 (CH3, NCH3), 44.32 (2CH2,
NCH2CH3), 114.45 (C, C-5), 149.30 (CH, C-8), 151.81 (C,
C-2), 154.70 (C, C-6), 163.03 (C, C-4); EIMS m/z 239 [M]?
(19), 241 [M?2] (6); 210 [M-C2H5], (100); HREIMS m/z
[M]? calcd. for C10H14ClN5 239.0937 found 239.0935.
2-Chloro-6-phenylamine-7-methylpurine 9c was obtained
as a white solid (0.18 g, 69 %); mp 202–203 C. (EtOH);
1H NMR (CDCl3), d: 3.96 (s, 3H, NCH3), 6.84 (s, 1H, NH),
7.23 (t, J = 7.20 Hz, 1H, p-C6H5), 7.40 (t, J = 7.20 Hz,
2H, m-C6H5), 7.52 (d, J = 7.20 Hz, 2H, o-C6H5), 7.90 (s,
1H, H-8); 13C NMR (DMSO-d6), d: 34.63 (CH3, NCH3),
112.40 (C, C-5), 123.17 (2CH, m-CH), 124.61 (CH, p-CH),
129.06 (2CH, o-CH), 138.97 (C, CNH), 148.47 (CH, C-8),
149.75 (C, C-2), 152.29 (C, C-6), 162.07 (C, C-4); FABMS
m/z 260 [M?1]? (100), 262 [M?1?2] (31.5); HREIMS
m/z [M]? calcd. for C12H10ClN5 259.0625 found 259.0626.
General synthesis of 2-substituted 7-methyl-6-
purinesulfenamide 10a–e
A solution of commercial NaOCl (14.5 %, 1.7 ml) and
1.7 ml of water was cooled to 0 C in an ice–NaCl bath.
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Ammonium hydroxide (25 %, 2 ml) was similarly cooled
and added with stirring to the bleach solution. The mixture
was stirred at -5 to 0 C for 15 min and then allowed to
cool to 0 C solution of 2-substituted 7-methyl-6-pur-
inethione 1a–d (2 mmol) in 10 % KOH (5 ml) was drop-
ped. The mixture was stirred in stoppered flask for 30 min
at temperature -5 to 0 C. The reaction mixture was
initially clear, light yellow solution, but after 30 min a
solid began separating. After allowing the reaction mixture
to stand at room temperature for an additional 1 h, the
precipitated product was filtered off and washed with a
small amount of cold water, followed by cold ethanol to
yield purine 6-sulfenamide 10a–c, 10e. The crude products
were purified by a column chromatography (silica gel,
CHCl3, CHCl3–EtOH, 99:1 v/v). The aqueous filtrate
separated after precipitation of product 10e was evaporated
to dryness and extracted with absolute ethanol (3 9 5 ml).
The ethanolic solvent was evaporated, and the residue was
purified by column chromatography (aluminum oxide,
CHCl3–EtOH, 10:1 v/v) to give compound 10d.
2-Chloro-7-methyl-6-purinesulfenamide 10a was ob-
tained as a yellow solid (0.35 g, 87.5 %); mp 149–150 C
(EtOH); 1H NMR (DMSO-d6), d: 3.98 (s, 3H, NCH3), 4.41
(s, 2H, NH2), 8.51 (s, 1H, H-8);
13C NMR (DMSO-d6), d:
35.13 (CH3, NCH3), 120.85 (C, C-5), 150.41 (CH, C-8),
152.99 (C, C-4), 159.88, 164.43 (C, C-2, and C-6);
FABMS m/z 216 [M?1]? (38), 218 [M?1?2] (12), 185
(100); HREIMS m/z [M]? calcd. for C6H6ClN5S 215.0032
found 215.0029.
2-Methoxy-7-methyl-6-purinesulfenamide 10b was ob-
tained as a yellow solid (0.39 g, 92.5 %); mp 158–159 C
(EtOH); 1H NMR (DMSO-d6), d: 3.93 (s, 6H, OCH3,
NCH3), 4.20 (s, 2H, NH2), 8.30 (s, 1H, H-8);
13C NMR
(DMSO-d6), d: 34.80 (CH3, NCH3), 54.81 (CH3, OCH3),
117.79 (C, C-5), 148.81 (CH, C-8), 160.55 (C, C-4),
161.72, 162.98 (C, C-2, and C-6); FABMS m/z 212
[M?1]? (100); HREIMS m/z [M]? calcd. for C7H9N5OS
211.0527 found 211.0523.
2-Methylthio-7-methyl-6-purinesulfenamide 10c was ob-
tained as a yellow solid (0.385 g, 85 %); mp 164–165 C
(EtOH); 1H NMR (DMSO-d6), d: 2.57 (s, 3H, SCH3), 3.94
(s, 3H, NCH3), 4.25 (s, 2H, NH2), 8.35 (s, 1H, H-8);
13C
NMR (DMSO-d6), d: 14.32 (CH3, SCH3), 34.86 (CH3,
NCH3), 119.06 (C, C-5), 151.57 (CH, C-8), 159.32 (C,
C-4), 161.52, 164.01 (C, C-2, and C-6); FABMS m/z 228
[M?1]? (100); HREIMS m/z [M]? calcd. for C7H9N5S2
227.0299 found 227.0299.
7-Methyl-6-sulfenamide-2-purinethione 10d was ob-
tained as a yellow solid (0.07 g, 16.5 %); mp 254–256 C
(EtOH); 1H NMR (DMSO-d6), d: 4.20(s, 3H, NCH3), 4.37
(s, 2H, NH2), 8.18 (s, 1H, H-8), 10.83 (s, 1H, NH);
13C
NMR (DMSO-d6), d: 34.68 (CH3, NCH3), 121.30 (C, C-5),
147.96 (CH, C-8), 157.40 (C, C-4), 169.22, 173.95 (C, C-2,
and C-6); FABMS m/z 214 [M?1] (100); HREIMS m/z
[M]? calcd. for C6H7N5S2 213.0143 found 213.0141.
7-Methyl-2,6-purinedisulfenamide 10e was obtained as a
yellow solid (0.315 g, 69 %); mp 185–186 C (EtOH); 1H
NMR (DMSO-d6), d: 3.94(s, 3H, NCH3), 4.03 (s, 2H,
NH2), 4.18 (s, 2H, NH2), 8.35 (s, 1H, H-8);
13C NMR
(DMSO-d6), d: 34.82(CH3, NCH3), 119.09 (C, C-5),
148.72 (CH, C-8), 159.45 (C, C-4), 161.26, 169.60 (C-2
and C-6); HSQC NMR, d: 8.35 (H-8) correlated with
148.72 (C-8), 3.94 (H, NCH3) correlated with 34.82 (C,
NCH3); HMBC NMR, d: 8.35 (H-8) correlated with 34.82
(C, NCH3), 119.09 (C-5), and 159.45 (C-4), 3.94 (H,
NCH3) correlated with 119.09 (C-5) and with 148.72 (C-8);
FABMS m/z 229 [M?1] (100); HREIMS m/z [M]? calcd.
for C6H8N6S2 228.0252 found 228.0255.
General synthesis of 2-substituted 7-methyl-6-
purinesulfonamide 8a–c, 8e
A solution of 3-chloroperbenzoic acid (MCPBA) (77 %,
0.86 g, 4 mmol) in 10 ml of ethanol was added dropwise
for 10 min to a solution of sulfonamides 10a–c and 10e
(1 mmol) in 79 ml of absolute ethanol. The mixture was
stirred at room temperature for 1.5 h, and a precipitated
solid was filtered off to give crude products 8a–c and 8e.
The ethanolic filtrate was evaporated to dryness and ex-
tracted with ether to remove 3-chlorobenzoic acid. The
solid residue together with crude product was purified by a
column chromatography (aluminum oxide, CHCl3, CHCl3–
EtOH, 9:1 v/v) to give also compounds 8a–c, 8e.
2-Chloro-7-methyl-6-purinesulfonamide 8a was obtained
as a white solid (0.18 g, 73 %); mp 174–175 C (EtOH);
1H NMR (DMSO-d6), d: 4.07 (s, 3H, NCH3), 6.91 (s, 2H,
NH2), 8.82 (s, 1H, H-8);
13C NMR (DMSO-d6), d: 36.46
(CH3, NCH3), 121.55 (C, C-5), 151.93 (CH, C-8), 153.88
(C, C-4), 160.39, 164.62 (C, C-2, and C-6); EIMS m/z 247
[M]? (1.5), 249 [M?2] (0.5); 183 [M-SO2] (14), 168 [M-
SO2NH2] (100); HREIMS m/z [M]
? calcd. for C6H6
ClN5O2S 246.9930 found 246.9927.
2-Methoxy-7-methyl-6-purinesulfonamide 8b was ob-
tained as a white solid (0.185 g, 76 %); mp 203–204 C.
(EtOH); 1H NMR (DMSO-d6), d: 3.88 (s, 3H, OCH3), 4.04
(s, 3H, NCH3), 7.99 (s, 2H, NH2), 8.70 (s, 1H, H-8);
13C
NMR (DMSO-d6), d: 35.86 (CH3, NCH3), 55.59 (CH3,
OCH3), 117.32 (C, C-5), 133.80 (CH, C-8), 153.60 (C,
C-4), 157.55, 166.54 (C, C-2, and C-6); EIMS m/z 243
[M]? (26), 180 [M-SO2] (55.5), 162 [M-SO2NH2] (8), 148
(100); HREIMS m/z [M]? calcd. for C7H9N5O3S 243.0426
found 243.0419.
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2-Methylthio-7-methyl-6-purinesulfonamide 8c was ob-
tained as a white solid (0.17 g, 66 %); mp 198–199 C
(EtOH); 1H NMR (DMSO-d6), d: 2.56 (s, 3H, SCH3), 4.03
(s, 3H, NCH3), 7.86 (s, 2H, NH2), 8.75 (s, 1H, H-8);
13C
NMR (DMSO-d6), d: 15.59 (CH3, SCH3), 34.04 (CH3,
NCH3), 116.45 (C, C-5), 129.28 (CH, C-8), 133.20 (C,
C-4), 147.01, 166.54 (C, C-2, and C-6); CIMS m/z 260
[M?1] (22), 196 [M?1-SO2] (64), 180 (M?1-SO2NH2]
(100); HREIMS m/z [M]? calcd. for C7H9N5O2S2
259.0198 found 259.0195.
7-Methyl-2,6-purinedisulfonamide 8d was obtained as a
white solid (0.23 g, 79 %); mp 214–215 C (EtOH); 1H
NMR (DMSO-d6), d: 4.17(s, 3H, NCH3), 7.01 (s, 2H,
NH2), 7.69 (s, 2H, NH2), 8.97 (s, 1H, H-8);
13C NMR
(DMSO-d6), d: 36.30 (CH3, NCH3), 122.52 (C, C-5),
154.76 (CH, C-8), 158.11 (C, C-4), 159.98, 162.99 (C, C-2,
and C-6); EIMS m/z 292 [M]? (9), 229 (M-SO2] (7), 149
[M-SO2 NH2] (22), 57 (100); HREIMS m/z [M]
? calcd. for
C6H8N6O4S2 292.0048 found 292.0044.
Antiproliferative assay in vitro
Cell culture
Compounds were evaluated for their anticancer activity us-
ing three cultured cell lines: SNB-19 (human glioblastoma,
DSMZ—German Collection of Microorganisms and Cell
Cultures, Braunschweig, Germany), C-32 (human amelan-
otic melanoma, ATCC—American Type Culture Collection,
Manassas, VA, USA), T47D (human ductal breast epithelial
tumor cell line, ATCC, Manassas, VA, USA), and HFF-1
(human fibroblast cell line, ATCC, Manassas, VA, USA).
The cultured cells were kept at 37 C and 5 % CO2. The cells
were seeded (1 9 104 cells/well/100 ll DMEM supple-
mented with 10 % FCS and streptomycin and penicillin)
using 96-well plates (Corning).
Proliferation
In recent years, tetrazolium salts have been described
which can be used for the measurement of cell proliferation
and viability. The tetrazolium salts are cleaved to formazan
by cellular enzymes. An expansion in the number of viable
cells results in an increase in the overall activity of mito-
chondrial dehydrogenases in the sample. This augmenta-
tion in enzyme activity leads to an increase in the amount
of formazan dye formed, which directly correlates with the
number of metabolically active cells in the culture. The
formazan dye produced by metabolically active cells is
quantified by a scanning ELISA reader by measuring the
absorbance of the dye solution at appropriate wavelengths
(k = 420–480 nm with a reference wavelength
k = 600 nm).
WST-1 assay
Antiproliferative effect of compounds was determined us-
ing the Cell Proliferation Reagent WST-1 assay (Roche
Diagnostics, Mannheim, Germany). After exposure to
tested compounds (at concentrations between 0 and
100 lg/ml) for 72 h, cells were incubated with WST-1
(10 ll) for 1 h, and the absorbance of the samples against a
background control was read at 450 nm using with a ref-
erence wavelength k = 600 nm a microplate reader. Re-
sults are expressed as means of at least two independent
experiments performed in triplicate.
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